Product Information
PROGLYCEM 50 MG/ML ORAL SUSP is a brand product labeled by Teva Pharmaceuticals USA Inc., priced at $16.4826 per ML under NDC 00575620030. Its NADAC has been published 472 times since Nov 28, 2013.
FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
50 mg/mL
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00575620030
Classification
Brand
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DIAZOXIDEApproval Type
New Drug (NDA)
FDA Application
NDA017453FDA Approved
Before 1982
TE Code
AB
On Market Since
9/30/1990
Price Statistics
The NADAC for PROGLYCEM 50 MG/ML ORAL SUSP has been published 472 times since Nov 28, 2013, and over the history we have for it it has risen 136.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $16.4826 per ML |
|---|---|
| All-time high | $16.9362 (May 13, 2026) |
| All-time low | $6.9693 (Nov 28, 2013) |
| 52-week high | $16.9362 |
| 52-week low | $15.2953 |
| Median price | $10.2519 |
| Average price | $10.9179 |
| Largest weekly change | +27.9% (Jul 17, 2024) |
| Weeks tracked | 472 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 55% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
diazoxide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PROGLYCEM 50 MG/ML ORAL SUSP?
The current National Average Drug Acquisition Cost (NADAC) for PROGLYCEM 50 MG/ML ORAL SUSP, manufactured by Teva Pharmaceuticals USA Inc., is $16.4826 per ML (NDC 00575620030), effective Sep 30, 2026.
How has the price of PROGLYCEM 50 MG/ML ORAL SUSP changed over time?
Over the history we have for it, the NADAC for PROGLYCEM 50 MG/ML ORAL SUSP has risen 136.5%. It has been tracked across 472 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for PROGLYCEM 50 MG/ML ORAL SUSP?
Since Nov 28, 2013, the NADAC for PROGLYCEM 50 MG/ML ORAL SUSP has ranged from a low of $6.9693 (Nov 28, 2013) to a high of $16.9362 (May 13, 2026), with a median of $10.2519 per ML.
Are there cheaper alternatives to PROGLYCEM 50 MG/ML ORAL SUSP?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, DIAZOXIDE 50 MG/ML ORAL SUSP, is $7.3764 per ML — about 55% below PROGLYCEM 50 MG/ML ORAL SUSP.
Who manufactures PROGLYCEM 50 MG/ML ORAL SUSP?
PROGLYCEM 50 MG/ML ORAL SUSP (NDC 00575620030) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a brand product.